ARYC President Dr Schena Discusses Q2 Performance In A Brief Interview

Aug. 16, 2013 1:55 AM ETARYC2 Comments
CBOE Trader profile picture
CBOE Trader's Blog
195 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Value, Special Situations

Contributor Since 2009

Delete

After our article on Arrayit (OTC:ARYC) we did a quick interview of Dr Mark Schena today and here's what he said about their Q2 performance:

Arrayit management is pleased to announce a strong operational quarter in Q2-2013. Revenue increased 19% YOY to $1.55M for the six months ended June 30, 2013 from $1.3M for the six months ended June 30, 2012. Gross margin increased 21% YOY to $0.71M for the six months ended June 30, 2013 from $0.59M for the six months ended June 30, 2012. Net income rose by $1.48M YOY to $0.16M for the six months ended June 30, 2013 compared to a $1.31M loss for the six months ended June 30, 2012. Net income attributable to common shareholders rose by $1.06M YOY to $0.16M for the six months ended June 30, 2013 compared to a $0.89M loss for the six months ended June 30, 2012. SG&A was reduced by $1.25M YOY to $0.49M for the six months ended June 30, 2013 compared to $1.74M for the six months ended June 30, 2012. Gross accounts receivable grew 8.3% YOY to $0.64M for the six months ended June 30, 2013 from $0.59M for the six months ended June 30, 2012.

During the three months ended June 30, 2013, the company raised $0.175M from an accredited investor, which will positively impact revenue and earnings in Q3-2013.

In our own assessment of the results, we noted a loss in sales mainly due to a delay in manufacturing. However, this was an operational issue which did not impact orders. Backload orders have improved to $0.29 million and ARYC posted lower gross margin of 37%, primarily due to decrease in sales of high margin microarray instruments and consumables.

Also, Arrayit has lower net loss from operations of $0.02 million compared to last period ($0.62 million), due to decline in consulting fees and legal expenses. The company has used cash of $0.92 million for its operations.

Currently, company has enough funds to carry out its operations for next 12 months, but needs additional funds. I expect that ARYC's focus on high margin microarray products will bring some positive outlook in the next year.

Disclosure: I am long OTC:ARYC.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.